Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes

Endocrinology, Diabetes & Metabolism
Ralph A DeFronzoSøren S Lund

Abstract

To analyse the effect of baseline glycated haemoglobin (HbA1c) on the reduction in HbA1c with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Using regression analyses of individual patient data from two Phase III studies, we compared the change in HbA1c according to a unit change in baseline HbA1c (the slope) with empagliflozin 10 mg or 25 mg vs sitagliptin (monotherapy) after 24 weeks, and with empagliflozin 25 mg vs glimepiride (as add-on to metformin) after 52 weeks. Steeper slopes of HbA1c decline were observed with empagliflozin 10 or 25 mg vs sitagliptin monotherapy at week 24. Regression analysis showed slopes of -0.59 (95% CI -0.70, -0.47), -0.49 (95% CI -0.62, -0.37) and -0.29 (95% CI -0.42, -0.15) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively (P < .001 and P < .05 for empagliflozin 10 mg and empagliflozin 25 mg, respectively, vs sitagliptin). Similarly, a steeper slope of HbA1c decline was observed with empagliflozin 25 mg vs glimepiride as add-on to metformin at week 52. Regression analysis showed slopes of - 0.52 (95% CI -0.59, -0.44) and -0.32 (95% CI -0.39, -0.25) for empagliflozin 25 mg and glimepiride, respectively (P < .001 for empagliflozin...Continue Reading

References

Mar 14, 2007·Endocrine Reviews·Bernardo L Wajchenberg
May 21, 2010·Diabetes Care·Diana SherifaliHertzel C Gerstein
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Feb 9, 2012·Nature Reviews. Endocrinology·Ele Ferrannini, Anna Solini
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators
Jun 21, 2014·The Lancet. Diabetes & Endocrinology·Martin RidderstråleUNKNOWN EMPA-REG H2H-SU trial investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.